Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

• Status: Active, not recruiting
• Trial end date: 2022-11-23
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Imatinib Mesylate; Niacinamide

Criteria

Inclusion Criteria:

1. Male or female patients ≥ 18 years of age with a confirmed diagnosis of Chronic Myeloid Leukemia in chronic phase (CML-CP).

2. Minimum of one year (12 calendar months) treatment with imatinib first line for CML-CP (patients have to be on imatinib 400 mg QD at randomization and had no dose change in the past three months).

For Korea only: (i)a minimum of one year (12 calendar months) of prior treatment with imatinib for patients with BCR-ABL levels > 0.1%, ≤ 1% IS at the time of randomization. (ii) a minimum of two years (24 calendar months) of prior treatment with imatinib for patients with BCR-ABL levels > 0.01%, ≤ 0.1% IS at the time of randomization.

3. BCR-ABL1 levels > 0.01% IS (International Scale) and ≤ 1% IS at the time of randomization as confirmed with a central assessment at screening; patients must not have achieved deep molecular response (MR4 IS) confirmed by 2 consecutive tests at any time during prior imatinib treatment. An isolated, single test result with BCR-ABL1 levels < 0.01 % (MR4 IS) is allowed, however, it should not have been observed within the 9 months prior to randomization

4. Patient must meet the following laboratory values before randomization:

• Absolute Neutrophil Count ≥ 1.5 x 10E9/L

• Platelets ≥ 75 x 10E9/L

• Hemoglobin ≥ 9 g/dL

• Serum creatinine < 1.5 mg/dL

• Total bilirubin ≤ 1.5 x ULN (Upper Limit of Normal) except for patients with Gilbert's syndrome who may only be included with total bilirubin ≤ 3.0 x ULN

• Aspartate transaminase (AST) ≤ 3.0 x ULN

• Alanine transaminase (ALT) ≤ 3.0 x ULN

• Alkaline phosphatase ≤ 2.5 x ULN

• Serum lipase ≤ 1.5 x ULN

5. Patients must have the following laboratory values ≥ Lower Limit of Normal or corrected to within normal limits with supplements prior to randomization: potassium increase of up to 6.0 mmol/L is acceptable if associated with creatinine clearance within normal limits ; calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with creatinine clearance* within normal limits) ; magnesium increase up to 3.0 mg/dL or 1.23 mmol/L if associated with creatinine clearance within normal limits.

Key Exclusion Criteria:

1. Treatment failure according to European Leukemia Network (ELN) criteria 2013 during imatinib treatment.

2. Known second chronic phase of CML after previous progression to Accelerated Phase (AP)/Blast Crisis (BC).

3. Previous treatment with any tyrosine kinese inhibitors (TKIs) other than imatinib.

4. History or current diagnosis of ECG abnormalities indicating significant risk or safety for subjects participating in the study such as:

• History of myocardial infarction, angina pectoris, coronary artery bypass graft within 6 months prior to randomization

• Concomitant clinically significant arrhythmias

• Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) prior to randomization

• Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

• Risk factors for Torsades de Pointes

• Concomitant medications with a "known" risk of Torsades de Pointes

• inability to determine the QTcF interval

5. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled clinically significant hyperlipidemia and high serum amylase)

6. History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis; on-going acute liver disease or history of chronic liver disease

7. History of other active malignancy within 3 years prior to randomization with the exception of basal cell skin cancer, indolent prostate cancer and carcinoma in situ treated curatively.

Other protocol defined inclusion/exclusion may apply.